CD274 and neoplasm: Of note, those responses were obtained regardless of tumor PD-L1 expression, questioning the ambiguous role of PD-L1 expression as a predictive biomarker. As long as safety is concerned, no dose-limiting AEs were observed during the first six weeks of treatment.